Connect
MJA
MJA

Transforming Australia’s Breast Implant Registry

Amy E Jeeves and Rodney D Cooter
Med J Aust 2012; 196 (4): . || doi: 10.5694/mja12.10117
Published online: 5 March 2012

A recall of breast implants from a French manufacturer has highlighted a low data capture rate — and considerable room for improvement — in Australia’s registry

Breast implants have long been a subject of media hype and controversy. Despite the debate surrounding the use of silicone prostheses in the 1990s, demand continues virtually unabated. Although Australia has a registry of breast implants, it has recently become clear that it contains insufficient data to provide comprehensive implant statistics. Growing concerns regarding lymphoma risk and the recall of one brand of implant have highlighted the need for more complete data on implantable breast devices.


  • 1 Royal Adelaide Hospital, Adelaide, SA.
  • 2 Waverley House Plastic Surgery Centre, Adelaide, SA.
  • 3 Australian Society of Plastic Surgeons, Sydney, NSW.



Competing interests:

No relevant disclosures.

  • 1. Scientific Committee on Emerging and Newly Identified Health Risks. The safety of PIP silicone breast implants: version of 1st February 2012. Brussels: European Commission, 2012. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_034.pdf (accessed Feb 2012).
  • 2. American Society of Plastic Surgeons. 2010 Plastic surgical procedural statistics. http://www.plasticsurgery.org/News-and-Resources/2010-Statistics.html (accessed Feb 2012).
  • 3. Terry MB, Skovron ML, Garbers S, et al. The estimated frequency of cosmetic breast augmentation among US women, 1963 through 1988. Am J Public Health 1995; 85: 1122-1124.
  • 4. Sanchez-Guerrero J, Colditz GA, Karlson EW, et al. Silicone breast implants and the risk of connective-tissue diseases and symptoms. N Engl J Med 1995; 332: 1666-1670.
  • 5. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000; 342: 781-790.
  • 6. Food and Drug Administration (US). Regulatory history of breast implants in the U.S. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/UCM064461 (accessed Feb 2012).
  • 7. Food and Drug Administration (US). FDA approves silicone gel-filled breast implants after in-depth evaluation [media release]. 17 Nov 2006. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2006/ucm108790.htm (accessed Feb 2012).
  • 8. Center for Devices and Radiological Health, Food and Drug Administration (US). FDA update on the safety of silicone gel-filled breast implants. June 2011. http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/UCM260090.pdf (accessed Feb 2012).
  • 9. Brinton LA, Lubin JH, Burich MC, et al. Mortality among augmentation mammoplasty patients. Epidemiology 2001; 12: 321-326.
  • 10. Brisson J, Holowaty EJ, Villeneuve PJ, et al. Cancer incidence in a cohort of Ontario and Quebec women having bilateral breast augmentation. Int J Cancer 2006; 118: 2854-2862.
  • 11. McLaughlin JK, Lipworth L, Fryzek JP, et al. Long-term cancer risk among Swedish women with cosmetic breast implants: an update of a nationwide study. J Natl Cancer Inst 2006; 98: 557-560.
  • 12. Deapen DM, Bernstein L, Brody GS. Are breast implants anticarcinogenic? A 14-year follow-up of the Los Angeles Study. Plast Reconstr Surg 1997; 99: 1346-1353.
  • 13. Angell M. Shattuck Lecture — evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. N Engl J Med 1996; 334: 1513-1518.
  • 14. Australian Government Department of Health and Ageing. Review of health technology assessment in Australia, December 2009. Canberra: DoHA, 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/00E847C9D69395B9CA25768F007F589A/$File/hta-review-report.pdf (accessed Feb 2012).
  • 15. Australian Society of Plastic Surgeons. Breast Implant Registry. http://www.plasticsurgery.org.au/default.aspx?itemid=112 (accessed Feb 2012).
  • 16. Agence française de sécurité sanitaire des produits de santé. Silicone filled breast implants manufactured by Poly Implant Prosthese (PIP) [media release]. 1 Apr 2010. http://www.afssaps.fr/var/afssaps_site/storage/original/application/ff8f7014c6ee1b6674c8fb7dd2835840.pdf (accessed Feb 2012).
  • 17. Therapeutic Goods Administration. Silicone gel breast implants manufactured by Poly Implant Prothese (PIP) of France. Consumer Information. 6 April 2010. http://www.tga.gov.au/safety/alerts-device-breast-implants-pip-100406.htm#201004 (accessed Feb 2012).
  • 18. Therapeutic Goods Administration. Currently no evidence of increased rupture rate for PIP breast implants in Australia, further investigations ongoing [media release]. 4 Jan 2012. http://www.tga.gov.au/newsroom/media-2012-pip-120104.htm (accessed Feb 2012).
  • 19. Therapeutic Goods Administration. Poly Implant Prothese (PIP) breast implants — the Australian perspective. 20 Jan 2012. http://www.tga.gov.au/safety/alerts-device-breast-implants-120120.htm (accessed Feb 2012).
  • 20. Summary of a pilot study on breast implantation outcomes carried out by an independent research group funded by the Department of Health. Feb 2006. http://www.mhra.gov.uk/Publications/Safetyguidance/CON2023228 (accessed Feb 2012).
  • 21. Duvic M, Moore D, Menter A, Vonderheid EC. Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol 1995; 32: 939-942.
  • 22. de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300: 2030-2035.
  • 23. Taylor KO, Webster HR, Prince HM. Anaplastic large cell lymphoma and breast implants: five Australian cases. Plast Reconstr Surg 2012. In press.
  • 24. Lipworth L, Tarone RE, McLaughlin JK. Breast implants and lymphoma risk: a review of the epidemiologic evidence through 2008. Plast Reconstr Surg 2009; 123: 790-793.
  • 25. Kim B, Roth C, Chung KC, et al. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg 2011; 127: 2141-2150.
  • 26. Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg 2011; 128: 629-639.
  • 27. Smith TJ, Ramsaroop R. Breast implant related anaplastic large cell lymphoma presenting as late onset peri-implant effusion. Breast 2012; 21: 102-104.
  • 28. Monash University. Registry Special Interest Group. http://www.registries. org.au/registryig.html (accessed Feb 2012).
  • 29. Australian Commission on Safety and Quality in Health Care. Operating principles and technical standards for Australian clinical quality registries. Sydney: ACSQHC, 2008.
  • 30. Graves SE, Davidson D, Ingerson L, et al. The Australian Orthopaedic Association National Joint Replacement Registry. Med J Aust 2004; 180 (5 Suppl): S31-S34. <MJA full text>
  • 31. Gabriel SE, Woods JE, O’Fallon WM, et al. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336: 677-682.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.